Clinical trial NCT02008019 - References

Chondrosarcoma — A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas

Citation(s)

•   Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS
  Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005 Nov 1;65(21):9953-61.
•   Dahlin DC, Unni KK Bone tumors: general aspects and data on 8542 cases
  Fourth ed. Sprinfield, Illinois: Charles C Thomas,1986.
•   Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ
  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001 Jun;7(6):1758-64.
•   Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ
  A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993 Jan;(286):241-6.
•   Enneking WF
  Musculoskeletal tumor surgery. Vol 2. New York, Churchill Livingstone, 1983: 875-997.
•   Evans HL, Ayala AG, Romsdahl MM
  Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977 Aug;40(2):818-31.
•   Faivre S, Kroemer G, Raymond E
  Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006 Aug;5(8):671-88. doi: 10.1038/nrd2062. Review.
•   Fingar DC, Blenis J
  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004 Apr 19;23(18):3151-71. Review.
•   Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, Mangham DC, Davies AM
  Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br. 2002 Jan;84(1):93-9.
•   Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ; North Central Cancer Treatment Group
  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005 Aug 10;23(23):5294-304. Epub 2005 Jul 5.
•   Gitelis S, Bertoni F, Picci P, Campanacci M
  Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am. 1981 Oct;63(8):1248-57.
•   Guigon CJ, Fozzatti L, Lu C, Willingham MC, Cheng SY
  Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis. 2010 Jul;31(7):1284-91. doi: 10.1093/carcin/bgq059. Epub 2010 Mar 18.
•   Hay N, Sonenberg N
  Upstream and downstream of mTOR. Genes Dev. 2004 Aug 15;18(16):1926-45. Review.
•   Hidalgo M, Rowinsky EK
  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000 Dec 27;19(56):6680-6. Review.
•   Huang S, Houghton PJ
  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 2002 Feb;3(2):295-304. Review.
•   Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC
  Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999 Mar;81(3):326-38.
•   Lichtenstein L, Jaffe HL
  Condrosarcoma of bone. Am J Pathol 1942; 19: 553-574.
•   MacKenzie AR, von Mehren M
  Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. Expert Rev Anticancer Ther. 2007 Aug;7(8):1145-54. Review.
•   Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, Giles F, Mita MM
  Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets. 2009 Oct;10(10):937-49. Review.
•   Marina N, Gebhardt M, Teot L, Gorlick R
  Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9(4):422-41. Review.
•   Meric-Bernstam F, Gonzalez-Angulo AM
  Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009 May 1;27(13):2278-87. doi: 10.1200/JCO.2008.20.0766. Epub 2009 Mar 30. Review.
•   Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R
  Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs. 2008 Nov;19(10):1019-21. doi: 10.1097/CAD.0b013e328312c0e5.
•   Miser JS, Pappo AS, Triche TJ et al
  In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Other soft tissue sarcomas of childhood. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:1017-1050.
•   Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F
  Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54. doi: 10.1517/13543780802556485 . Review.
•   O'Donnell A, Faivre S, Judson I et al
  A phase I study of the oral mTOR inhibitors RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc Am Soc Clin Oncol 2003;22:803a
•   O'NEAL LW, ACKERMAN LV
  Chondrosarcoma of bone. Cancer. 1952 May;5(3):551-77.
•   Pring ME, Weber KL, Unni KK, Sim FH
  Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am. 2001 Nov;83-A(11):1630-42. Review.
•   Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE
  Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer. 1980 Jan 1;45(1):149-57.
•   Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP
  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004 Jun 15;22(12):2336-47. Epub 2004 May 10.
•   Wan X, Mendoza A, Khanna C, Helman LJ
  Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005 Mar 15;65(6):2406-11.

A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas

Details for clinical trial NCT02008019